

AMENDMENTS TO THE SPECIFICATION:

Please amend the specification as follows:

In the Abstract, as shown in the Amendment filed on December 13, 2004,
kindly amend the first paragraph as follows:

The invention relates to a novel group of phenylpiperazines having interesting pharmacological properties such as a high affinity for the dopamine D₂ receptor and/or the serotonin reuptake site, and the ability to treat conditions related to disturbances in the dopaminergic and/or the serotonergic systems such as aggression, anxiety disorders, autism, vertigo, depression, disturbances of cognition, disturbances of memory, Parkinson's disease, schizophrenia, and psychotic disorders.